Pharsight Announces Cooperative Research Agreement with FDA for its Clinical Trial Simulator and Population Modeling Software.Business Editors and Health/Medical Writers MOUNTAIN VIEW, Calif.--(BW HealthWire)--Feb. 13, 2001 Goal is to collaboratively explore and enhance software tools for use in clinical trial drug development Pharsight Corporation, (Nasdaq:PHST PHST Pädagogische Hochschule Steiermark (Graz, Austria school) PHST Packaging, Handling, Storage & Transport(ation) PHST Packing Handling Storage & Transporting ) the leading provider of technologies and services for accelerating pharmaceutical development, today announced the approval of a Cooperative Research and Development Agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation). A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. (CRADA CRADA Cooperative Research And Development Agreement ) with the Food and Drug Administration's (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) Center for Drug Evaluation and Research The Center for Drug Evaluation and Research is a division of the FDA that deals with the approval of drugs. CDER reviews New Drug Applications to ensure that the drugs are safe and effective. It is one of five Centers at the United States Food and Drug Administration. (CDER CDER Center for Drug Evaluation and Research (US FDA) CDER Centre de Développement des Energies Renouvelables (French) CDER Client Development and Evaluation Report ) to further develop products using clinical drug trial simulation and population pharmacokinetic (PK) analysis software to support the drug development process. Under the agreement, CDER and Pharsight will collaborate on future versions of Pharsight's WinNonMix(R) and Pharsight(R) Trial Simulator(TM) products over a three-year term. The goal of the collaboration is to address evolving industry and regulatory needs for population PK/PD PK/PD Pharmacokinetic/Pharmacodynamic (pharmacokinetic/pharmacodynamic) modeling and clinical trial simulation. "This collaboration is expected to benefit both organizations and potentially the pharmaceutical industry as well. By combining the needs of the agency with the needs of the industry we can create better products for clinical development, design and evaluation," said Daniel Weiner, Ph.D., Pharsight's senior vice president of technology deployment. Population PK/PD studies are designed to determine important sources of variability in drug concentrations and effects among individual subjects of a target population who participate in the clinical testing of a new drug. Population PK/PD analysis makes it possible to identify relevant intrinsic and extrinsic EVIDENCE, EXTRINSIC. External evidence, or that which is not contained in the body of an agreement, contract, and the like. 2. It is a general rule that extrinsic evidence cannot be admitted to contradict, explain, vary or change the terms of a contract or of a (demographic or physiological) variables that contribute to the differences in patient blood level profiles and pharmacodynamic outcomes. These results can be valuable in planning later phases of clinical trials. By using these software tools to better explain the measurable factors that may be related to both the change and the magnitude of change in outcomes, more appropriate directions for dosage, administration and labeling for new drugs may be achieved. "While population modeling and trial simulation tools have become increasingly important to the pharmaceutical development process, technological advances now make it possible to develop additional user-friendly scientific software to help integrate these multiple sources of input into the planning and review processes," Weiner said. "This could enable more efficient clinical trial design and evaluation." Pharsight will provide software products, consulting and training and will collaborate with CDER to develop software solutions. About Pharsight Corporation Pharsight Corporation (Nasdaq:PHST) develops and markets integrated products and services that help pharmaceutical and biotechnology companies improve the drug development process. The company's solutions combine proprietary computer-based simulation, statistical and data analysis tools with the sciences of pharmacology, drug and disease modeling, human genetics Human genetics A discipline concerned with genetically determined resemblances and differences among human beings. Technological advances in the visualization of human chromosomes have shown that abnormalities of chromosome number or structure are surprisingly , biostatistics and strategic decision-making. Pharsight Corporation is headquartered in Mountain View, California For the census-designated place, see Mountain View, Contra Costa County, California. For other places called "Mountain View", see . Mountain View is a city in Santa Clara County, in the U.S. state of California. The city gets its name from the views of the Santa Cruz Mountains. . Information about Pharsight is available on the World Wide Web at http://www.pharsight.com. This press release contains forward-looking statements related to the future development of products under this CRADA and the benefits to be obtained. Actual results may differ as a result of numerous risks and uncertainties, including the risk that the collaboration may not yield expected results due to unexpected technical or other difficulties, or that customers may not perceive the benefits of the resulting products as Pharsight perceives them. Note to Editors: Pharsight and WinNonMix are registered trademarks, and Trial Simulator is a trademark of Pharsight Corporation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion